ProteinLogic and Stellenbosch University receive $1.3 million grant to develop blood test to monitor response to TB antimicrobial chemotherapy
Summary
PTNG Consulting will oversee the project management of this undertaking.ProteinLogic has forged a partnership with Stellenbosch University, South Africa, renowned for their significant contributions to global TB research. The non-dilutive funding from the Gates Foundation will allow ProteinLogic and Stellenbosch University to determine whether the use of ImmiPrint\xae technology can be extended to the monitoring of clinical responses to TB antimicrobial therapy.Tuberculosis is one of the worlds deadliest diseases, killing about 3600 people per day in 2022. Reducing the cost of research and development and enabling physicians to determine treatment outcomes in a timely manner will aid directly in the development of novel anti-TB chemotherapies.Peter Klimt, Chairman of ProteinLogic, commented: ProteinLogics ImmiPrint\xae technology provides the basis of a universal protein based search engine for the rapid, efficient, and cost-effective discovery of diagnostic biomarker signatures that address multiple disease categories. For further information please visit https://www.proteinlogic.com.About Stellenbosch UniversityStellenbosch University (SU) is a proudly African knowledge hub that serves our country and continent through excellent education, research, and innovation. The companys highly experienced scientists use cutting-edge computational tools in combination with decades of experimental knowledge to de-risk clients projects and improve their chances for clinical success.